GW&K Investment Management LLC Has $21.64 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

GW&K Investment Management LLC trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 1.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 2,884,680 shares of the biotechnology company's stock after selling 56,716 shares during the period. GW&K Investment Management LLC owned 1.38% of BioCryst Pharmaceuticals worth $21,635,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of BCRX. Proficio Capital Partners LLC bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $192,000. Raymond James Financial Inc. bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $80,000. Swiss National Bank increased its holdings in BioCryst Pharmaceuticals by 6.2% in the fourth quarter. Swiss National Bank now owns 386,568 shares of the biotechnology company's stock valued at $2,907,000 after purchasing an additional 22,600 shares during the period. Cibc World Markets Corp acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $145,000. Finally, Intech Investment Management LLC lifted its holdings in BioCryst Pharmaceuticals by 80.3% during the 4th quarter. Intech Investment Management LLC now owns 97,793 shares of the biotechnology company's stock worth $735,000 after buying an additional 43,556 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX traded up $0.02 during trading hours on Friday, hitting $8.57. The stock had a trading volume of 806,786 shares, compared to its average volume of 3,843,500. The firm has a 50 day simple moving average of $9.80 and a 200-day simple moving average of $8.70. The firm has a market capitalization of $1.79 billion, a P/E ratio of -32.90, a price-to-earnings-growth ratio of 1.41 and a beta of 1.04. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.01 and a 1-year high of $11.31.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Barclays increased their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target for the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Finally, Wedbush increased their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, June 30th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.